杭州市儿童急性呼吸道Saffold心病毒感染的临床特征及流行病学分析

目的 了解杭州地区Saffold心病毒（SAFV）在急性呼吸道感染（ARI）患儿中的临床特征和流行病学特征.方法 收集2011年3月至2014年2月浙江大学医学院附属儿童医院呼吸道门诊和住院病例共1060例.其中门诊病例采集咽拭子256份,住院病例采集气管吸取物804份.实时荧光PCR扩增SAFV的5＇UTR基因片段.采用SPSS 17.0软件分析检测结果和临床资料.结果ARI门诊患儿和住院患儿样本中SAFV的检出率分别是2.3%（6/256）和13.2%（106/804）,两者相比差异具有统计学意义（χ^2=24.147,P〈0.01）.住院病例中,〈1岁、1~〈3岁、3~〈6岁和6~12岁患儿阳性检出率分别为14.0%、11.2%、11.1%和8.3%,各年龄组间相比,差异无统计学意义（χ^2=1.845,P〉0.05）;男性和女性患儿 SAFV 检出率分别为12.7%和17.7%（χ^2=0.279,P 〉0.05）;按季节划分,SAFV检出率最高的是秋季（21.2%）,其次是春季（14.6%）,冬季（9.5%）和夏季（8.8%）检出率相对较低（χ^2=15.625,P〈0.01）.106例SAFV阳性住院患儿中,81例存在合并感染,合并感染率为76.4%.6例门诊病例中,4例存在合并感染,合并感染率为66.7%.住院病例中,与SAFV合并感染率最高的是呼吸道合胞病毒（36.8%）,其次为鼻病毒（27.4%）、偏肺病毒（10.4%）和副流感病毒（10.4%）.ARI患儿中,SAFV阳性病例的发热率低于SAFV阴性病例（χ^2=4.069,P〈0.05）.结论 杭州地区ARI住院患儿中SAFV的检出率显著高于门诊患儿,SAFV感染均以合并感染为主.SAFV在杭州地区的流行呈现一定地方流行模式.

Saffold心病毒对人类感染的研究进展

Saffold心病毒（SAFV）是近年来从人体分离到的一种新的心病毒,至今已发现11种基因型.SAFV感染多见于6岁以下儿童,可通过粪-口途径和呼吸道传播,临床上常引起急性胃肠炎、呼吸道及中枢神经系统感染,后者可致重症脑炎.此文结合国内外相关文献,就SAFV的特性、感染人类的情况作了综述,以期引起儿科及感染科医师对该病毒的重视.

Efficacy and safety of therapeutic angiogenesis from direct myocardial administration of an adenoviral vector expressing vascular endothelial growth factor 165

OBJECTIVE: To investigate whether direct administration of adenoviral vectors (Ad) containing the complementary deoxyribonucleic acid (cDNA) of vascular endothelial growth factor 165 (Ad-VEGF165) induces porcine coronary collateral vessel formation, improves regional myocardial perfusion and function and is safe. METHODS: Three weeks after miniature swine underwent left thoracotomy and placement of an Ameroid constrictor on the left circumflex coronary artery (LCX), Ad-VEGF165 (n = 6) or the control, Ad expressing beta-galactosidase cDNA (Ad-Gal, n = 6), was directly administered into the ischemic myocardium in the circumflex distribution. All animals were sacrificed 4 wk after the second surgery. Myocardial perfusion and function were assessed by electrocardiogram-gated single photon emission computed tomography (GSPECT) imaging. Ex vivo coronary angiography was performed to examine collateral vessels. Toxicity was assessed by blood analyses on the day just before (day 0) and on day 1, 3, 7, 28 after vector delivery and by vascular, myocardial and liver histology after sacrifice. RESULTS: GSPECT imaging 4 wk after administration of Ad-VEGF165 demonstrated significant reduction in ischemic area (P